- Home
- PRCH vs GHRS Comparison
PRCH vs GHRS Comparison
Compare PRCH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCH | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRCH | GHRS |
|---|---|---|
| Price | $21.37 | $18.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $25.43 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 2.2M | 309.1K |
| Earning Date | 10-28-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $9.86 | N/A |
| Revenue Next Year | $32.75 | N/A |
| P/E Ratio | $200.00 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $6.36 | $12.04 |
| 52 Week High | $22.36 | $31.44 |
Technical Indicators
Market Signals| Indicator | PRCH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 38.73 |
| Support Level | $15.90 | $17.54 |
| Resistance Level | N/A | $22.51 |
| Average True Range (ATR) | 1.26 | 1.28 |
| MACD | 0.19 | 0.13 |
| Stochastic Oscillator | 84.16 | 14.63 |
Price Performance
Historical ComparisonAbout PRCH Porch Group Inc.
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.